Statin Intolerance: an Overview of the Current Status and Possible Treatment Options.
- Author:
Sunghwan SUH
1
;
Chang Hee JUNG
;
Soon Jun HONG
;
Jung Sun KIM
;
Sung Hee CHOI
Author Information
- Publication Type:Review
- Keywords: Statins; Lipids; Cardiovascular disease
- MeSH: Antibodies, Monoclonal; Bile; Cardiovascular Diseases; Cause of Death; Cholesterol; Creatinine; Dyslipidemias; Ezetimibe; Food Habits; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors*; Hyperlipoproteinemia Type II; Korea; Lipoproteins; Orphan Drug Production; Phosphotransferases; Proprotein Convertases; Rhabdomyolysis
- From:Journal of Lipid and Atherosclerosis 2018;7(2):77-87
- CountryRepublic of Korea
- Language:English
- Abstract: Lowering serum low-density lipoprotein cholesterol (LDL-C) is the mainstay for reduction of risk of cardiovascular disease (CVD), the second most common cause of death in Korea. The 2015 Korean guidelines for management of dyslipidemia strongly recommend the use of statins in patients at risk of CVD. Statin therapy, which is the gold standard for CVD, reduces LDL-C level by 40% to 60% and is generally well tolerated. However, many patients are intolerant to statins and discontinue therapy or become nonadherent to therapy because of actual/perceived side effects. The most common of these side effects is the statin-associated muscle symptom (SAMS). Discontinuation and repetitive re-challenge with statins can help identify SAMS. If serum creatinine kinase level is more than 10 times the upper limit of normal, statin therapy must be stopped immediately, and the physician should identify possible causes including rhabdomyolysis and treat appropriately. In other patients, it might help to switch to a less potent statin or to use statins at intermittent non-daily dosing. To achieve target LDL-C level, non-statin lipid-lowering therapies such as dietary modifications, ezetimibe, and bile acid sequestrants may be added. Several new drugs have recently been approved for lowering LDL-C level. Alirocumab and evolocumab are monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, and both drugs cause large reductions in LDL-C, similar to statins. Lomitapide and mipomersen are orphan drugs used as adjuncts to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia.
